Bloomberg Law
Free Newsletter Sign Up
Login
BROWSE
Bloomberg Law
Welcome
Login
Advanced Search Go
Free Newsletter Sign Up

Roche’s Chugai Sues Alexion to Block Sales of Ultomiris Drug

Nov. 12, 2019, 10:07 PM

Roche’s Chugai unit said Alexion’s Ultomiris, used to treat rare life-threatening blood diseases, infringes its patent.

  • Roche is seeking cash compensation of “any available damages” and a court order blocking U.S. sales of Ultomiris, according to a complaint filed Tuesday in federal court in Wilmington, Delaware
  • Ultomiris is taken every eight weeks, a more convenient dosing than Alexion’s blockbuster Soliris, which is taken every two weeks
    • The drugs are used to treat potentially fatal blood diseases including paroxysmal nocturnal hemoglobinuria (PNH)
  • Alexion sells both Soliris and Ultomiris, but makes most of its revenue from Soliris sales, making it ...